Genticel, a Paris and Toulouse, France-based a vaccine developer that focuses on therapeutic vaccines against high risk human papillomavirus (HPV) infection, raised €18.2m ($23.7m) in funding.
The round was led by Wellington Partners, with participation from current investors IDInvest Partners, Edmond de Rothschild Investment Partners (EdRIP), InnoBio fund, IRDI and Amundi Private Equity Funds. In conjunction with the funding, Dr. Rainer Strohmenger, general partner at Wellington Partners, joined the supervisory board of Genticel.
The company intends to use the funds to advance its two therapeutic HPV vaccines. The lead vaccine, ProCervix, has finished phase I clinical study and will enter into phase II development in order to demonstrate proof of efficacy. Its other pipeline product is a CyaA-based multivalent HPV vaccine with additional virus subtype coverage.
Genticel is led by Benedikt Timmerman, founder and CEO.